Version 2 2020-05-07, 07:56Version 2 2020-05-07, 07:56
Version 1 2020-05-07, 07:55Version 1 2020-05-07, 07:55
journal contribution
posted on 2020-05-07, 07:56authored byA Collins, GJ Miles, J Wood, M MacFarlane, C Pritchard, E Moss
The majority of endometrial cancers are detected early with a favourable prognosis. However, for patients with advanced disease, chemotherapy response rates and overall survival remains poor. The endometrial cancer population is typically elderly with multiple co-morbidities and aggressive cytotoxic therapy may be hazardous. Therefore, there is an urgent need to define optimal treatment strategies for advanced and recurrent disease and personalise therapy based on individual tumour and patient characteristics. Three-dimensional (3D) models that preserve the tumour microenvironment and tumour-stromal interactions are increasingly important for translational research with the advent of immunotherapy and molecularly targeted agents. 3D patient-relevant pre-clinical models in endometrial cancer include spheroids, patient-derived organoids, microfluidic systems, patient-derived xenografts and patient-derived explants. Here we present a review of available 3D modelling systems in endometrial cancers, highlighting their current use, advantages, disadvantages and applications to translational research with a focus on the power of the patient-derived explant platform.
Funding
This research was supported and funded by the Explant Consortium comprising four partners: The University of Leicester, The MRC Toxicology Unit, Cancer Research UK Therapeutic Discovery Laboratories and LifeArc. Additional support was provided by the CRUK-NIHR Leicester Experimental Cancer Medicine Centre (C10604/A25151) and Hope Against Cancer. Funding for Gareth Miles was provided by Breast Cancer Now’s Catalyst Programme (2017NOVPCC1066), which is supported by funding from Pfizer.
History
Citation
Gynecologic Oncology
Volume 156, Issue 1, January 2020, Pages 251-259